论文部分内容阅读
目的:探究分析低分子治疗小儿肾病综合症的临床治疗效果,为相关临床治疗提供有效依据。方法:随机选取该院2015年1月至2016年1月接受治疗的80例原发性肾病综合症患儿为研究对象,对照组进行对患儿给予免疫抑制剂及激素类药物的常规治疗,观察组在常规治疗的基础上增加使用低分子肝素进行治疗,对比两组患者治疗后的临床症状变化,对其治疗效果进行评价对比。结果:观察组患儿在治疗后的24h尿蛋白,血清白蛋白,总胆固醇及D-二聚体数据均优于对照组。结论:低分子治疗小儿肾病综合症的临床效果显著,并未发生出血及肝功能损伤等并发症的不良反应,为小儿肾病综合症临床治疗提供有效依据,值得推广应用。
Objective: To explore the clinical therapeutic effect of low molecular weight treatment of children with nephrotic syndrome, and to provide an effective basis for the relevant clinical treatment. Methods: A total of 80 children with primary nephrotic syndrome who were treated in our hospital from January 2015 to January 2016 were randomly selected. The control group was given routine immunotherapy and hormone therapy. The observation group was treated with LMWH on the basis of routine treatment, and the changes of clinical symptoms were compared between the two groups after treatment, and the treatment effect was evaluated and compared. Results: The data of 24h urinary protein, serum albumin, total cholesterol and D-dimer in the observation group were better than those in the control group. Conclusion: The therapeutic effect of low molecular weight nephrotic syndrome in children is remarkable. No adverse reactions such as hemorrhage and liver injury are found. It is an effective basis for the clinical treatment of children with nephrotic syndrome and should be popularized and applied.